Semaglutide – 10mg

Semaglutide is a long acting synthetic analogue of glucagon like peptide 1 (GLP-1) with a half-life of approximately 7 days achieved through fatty acid chain conjugation enabling albumin binding and protection against DPP-4 enzymatic degradation. iLab Pharma’s formulation supplies 10mg as a lyophilized vial, a reconstitute format that differs meaningfully from CSD’s prefilled pen Semaglutide presentation, providing researchers with precise solution concentration control, flexible dosing across a broader concentration range, and suitability for in vitro GLP-1 receptor binding studies and parenteral administration research protocols where the fixed dose pen format’s convenience features are less relevant than dosing adjustability.

The lyophilized vial format serves distinct research purposes from the prefilled pen within CSD’s Semaglutide range. The 9.6mg prefilled pen delivers four fixed 2.4mg doses in a ready to use system suited to protocols examining Semaglutide at the higher end of the clinically referenced concentration range with administration convenience as a priority. The 10mg lyophilized vial provides a larger total compound supply with researcher controlled reconstitution concentration, enabling dose titration across a broader range, multi group experimental designs drawing from a single compound source, and in vitro applications where precise solution concentration is a critical variable that prefilled delivery systems cannot accommodate.

Semaglutide’s well documented pharmacological profile as the most clinically advanced GLP-1 receptor agonist in current research including its landmark cardiovascular outcomes trial data, regulatory approvals across diabetes and obesity indications, and fatty acid chain albumin binding mechanism producing once weekly dosing. It remains consistent across both CSD presentations. Within the broader incretin research family, Semaglutide’s pure GLP-1 receptor selectivity continues to position it as the single receptor reference standard against which CSD’s dual and triple incretin agonist listings are compared in comparative receptor pathway research.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks Semaglutide across two formats: this iLab Pharma 10mg lyophilized vial and the prefilled pen 9.6mg presentation. Giving researchers delivery format flexibility within the same compound from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside dual and triple incretin agonist compounds in comparative GLP-1 receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.